Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Cesar Aleman

General Practice Carrollton, TX Medical Doctor

NPI 1336172824 CMS profile 196482

4541 N Josey Ln Ste 110, Carrollton, TX 75010

Open in the dashboard

General payments

$3,697

145 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Cesar Aleman of Carrollton, TX is reported in the CMS Open Payments database as having received $3,697 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $332 12
2021 General $674 40
2020 General $878 42
2019 General $1,813 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cesar Aleman
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Cesar Aleman were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Cesar Aleman General Practice median Middle half National median
2019 $1,813 $107 $37–$285 $163
2020 $878 $75 $25–$213 $114
2021 $674 $93 $30–$272 $132
2022 $332 $103 $36–$279 $149
2023 $0 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $937 34 payments
  2. Novo Nordisk Inc $666 28 payments
  3. Amarin Pharma Inc. $450 13 payments
  4. Janssen Pharmaceuticals, Inc $433 6 payments
  5. Lilly USA, LLC $360 23 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $289 16 payments
  7. Genzyme Corporation $180 2 payments
  8. Sanofi-Aventis U.S. LLC $82 5 payments
  9. Arbor Pharmaceuticals, Inc. $53 4 payments
  10. Amgen Inc. $50 2 payments
  11. Other $198 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,502 141 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $180 2 payments
  3. Education $14 2 payments
Products named General payments · program years 2019–2022
  1. FARXIGA $846 28 payments
  2. Ozempic $486 19 payments
  3. JARDIANCE Diabetes $289 16 payments
  4. INVOKANA $280 3 payments
  5. Vascepa Hypertriglyceridemia $250 2 payments
  6. JARDIANCE Diabetes $226 14 payments
  7. TRULICITY $219 16 payments
  8. Tresiba $219 11 payments
  9. Vascepa Cardiovascular $200 11 payments
  10. XARELTO $153 3 payments
  11. Other $1,055 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record